Rekvina Laboratories accepts resignation of MD Amit Mukesh Shah

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Rekvina Laboratories accepts resignation of Amit Mukesh Shah as MD and Director
  • Effective date of resignation is September 11, 2026
  • Cited reason is personal commitments and personal reasons
  • Filing made to BSE under Regulation 30 of SEBI Listing Regulations
powered bylight_fuzz_icon
50770317

*this image is generated using AI for illustrative purposes only.

Rekvina Laboratories has accepted the resignation of Amit Mukesh Shah from the positions of Managing Director and Director, effective September 11, 2026.

The company disclosed the development in a filing with the Bombay Stock Exchange on September 12, 2026. The intimation was issued pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Resignation Details

Mr. Shah tendered his resignation due to personal reasons and personal commitments. In his letter to the Chairman, dated September 11, 2026, he confirmed that his departure is solely attributable to these factors and stated there are no other reasons for his resignation.

The Board of Directors formally accepted the resignation through a communication signed by Surbhit Mukesh Shah, Director, on September 12, 2026. The filing included details required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

No financial data or operational metrics were disclosed in this regulatory filing.

Historical Stock Returns for Rekvina Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+1.99%+12.54%+93.61%+102.66%0.0%0.0%

Who has been appointed or nominated as the interim Managing Director to ensure operational continuity during the transition?

Will Rekvina Laboratories initiate a search for a permanent replacement for Amit Mukesh Shah, and what is the expected timeline for this process?

How might this leadership change impact the company's ongoing strategic initiatives or R&D pipeline at Rekvina Laboratories?

Rekvina Laboratories FY26 Results: Net loss widens 86% to ₹25.47 lakh

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Net loss widened to ₹25.47 lakh in FY26 from ₹13.71 lakh in FY25
  • Revenue from operations began at ₹126.54 lakh after nil in prior year
  • Borrowings rose sharply to ₹147.27 lakh, mostly from related parties
  • Board approved AGM notice and new independent director appointments
powered bylight_fuzz_icon
49981120

*this image is generated using AI for illustrative purposes only.

Rekvina Laboratories reported a net loss of ₹25.47 lakh for FY26, widening from a loss of ₹13.71 lakh in the previous fiscal year. The company recorded revenue from operations of ₹126.54 lakh, marking its first operational income after a period of suspension.

The board approved the financial statements and the AGM notice on September 3, 2026. The annual general meeting is scheduled for September 29, 2026.

Financial Performance

Rekvina Laboratories commenced operations in FY26, generating total income of ₹126.54 lakh compared to nil in FY25. However, total expenses surged to ₹152.01 lakh from ₹13.71 lakh, driven primarily by purchases of stock-in-trade (₹118.16 lakh) and employee benefits (₹22.99 lakh).

Metric FY26 FY25 Change
Revenue ₹126.54 lakh Nil New Operations
Total Expenses ₹152.01 lakh ₹13.71 lakh Significant Rise
Net Loss ₹25.47 lakh ₹13.71 lakh Widened

Balance Sheet Signals

Borrowings increased significantly to ₹147.27 lakh from ₹24.69 lakh, largely comprising unsecured loans from related parties. The company’s equity stood at negative ₹122.82 lakh, reflecting accumulated losses and a prior-period error adjustment of ₹64.13 lakh for historical listing and filing fees.

What the Numbers Show

The divergence between operational commencement and profitability is stark. While the company generated ₹126.54 lakh in sales, it incurred a net loss of ₹25.47 lakh. This indicates that the initial cost structure—particularly employee benefits and procurement costs—exceeded the revenue generated in this first year of active trading.

Corporate Governance

The board noted the resignation of Company Secretary Deepak Khandelwal effective September 2, 2026. It also recommended the reappointment of Mrs. Ilaben Pathak and the appointment of Mr. Prateek Jain and Mr. Jay Chintan Patel as independent directors.

Historical Stock Returns for Rekvina Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+1.99%+12.54%+93.61%+102.66%0.0%0.0%

What specific operational milestones or revenue targets has Rekvina Laboratories set for FY27 to bridge the gap between its current cost structure and profitability?

How will the significant increase in unsecured related-party borrowings impact the company's future financing options and interest burden?

What is the strategic rationale behind appointing three new independent directors, and how might this reshape the board's oversight of the company's turnaround plan?

More News on Rekvina Laboratories

1 Year Returns:0.00%